Ligand-receptor interactions of V-domain Ig-containing suppressor of T cell activation and programmed death-1 suppress the anticancer activities of T cells
These results open a completely new chapter in our understanding of the concept of immune checkpoint proteins, where some of them clearly show both ligand and receptor activities and display multifunctional properties.
Authors
- Elizaveta Fasler‐Kan (ORCID: https://orcid.org/0000-0002-4466-2642)
- Dietmar Cholewa (ORCID: https://orcid.org/0000-0002-8100-0365)
- Maryam Abooali
- Vadim V. Sumbayev (ORCID: https://orcid.org/0000-0002-9404-5626)
- Inna M. Yasinska (ORCID: https://orcid.org/0000-0002-0775-1689)
- Giuliano Siligardi (ORCID: https://orcid.org/0000-0002-4667-6423)
- Steffen Berger (ORCID: https://orcid.org/0000-0002-9310-3548)
- Stephanie Schlichtner (ORCID: https://orcid.org/0000-0002-8743-7795)
- Lei Xi (ORCID: https://orcid.org/0000-0001-7076-3124)
- Bernhard F. Gibbs (ORCID: https://orcid.org/0000-0002-0537-228X)
- Tiberiu‐Marius Gianga (ORCID: https://orcid.org/0000-0002-6081-874X)
- Rohanah Hussain (ORCID: https://orcid.org/0000-0001-6207-6631)
Institutions
- Canterbury Christ Church University (GB)
- Medway School of Pharmacy (GB)
- Medical University of Graz (AT)
- Diamond Light Source (GB)
- University Children’s Hospital Bern (CH)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-11-17
- DOI
- https://doi.org/10.1016/j.iotech.2025.101533
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00